Akero Therapeutics, Inc. is a clinical-stage biotechnology company that is focused on developing and commercializing treatments for serious metabolic diseases. The Company is engaged in nonalcoholic steatohepatitis (NASH), a disease without any approved therapies. NASH is a severe form of nonalcoholic fatty liver disease, or NAFLD, characterized by inflammation and fibrosis in the liver that can progress to cirrhosis, liver failure, cancer and death. The Company’s lead product candidate, AKR-001, which the Company is developing as a treatment for patients with NASH, is an analog of fibroblast growth factor 21 (FGF21). FGF21 is an endogenously-expressed hormone that regulates metabolism of lipids, carbohydrates and proteins throughout the body.
Market Cap:633.9M; Shares Outstanding:28.6M; Short Interest: 2.33%; Q3 2019(9/30/19): Cash 148M. Loss 15.55M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 71，no change
Shares hold: 13040.1k shares. no change
shares% hold: 45.66%，no change